October 7, 2014 | The Israeli pharmaceutical company developed an ADHD treatment drug, Alcobra Pharma announced positive results in a Phase III clinical trial on the drug. The drug, Metadoxine Extended Release (MDX), will be used in adults to treat ADHD. However, the market did not respond positively to the news, with the company’s share price dropping 45.36 percent in premarket trading to $7.71 at a market cap of $192.77 million. According to the company, MDX showed statistically significant improvement in ADHD symptoms compared to a placebo when measured on the Conner’s Adult ADHD Rating Scale. The trial was conducted on 300 patients at 18 sites in the United States and 2 in Israel. Alcobra Pharma is headed by CEO Yaron Daniely.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Tech Deters Distracted Drivers In New Italian Pilot
November 28, 2023

German Health Firm Enlists Israeli 3D Printer To Boost CT Imaging
November 28, 2023

Biotech Firm Unveils New Inflammatory Disease, Cancer Therapy
November 27, 2023

Global Money Transfer Firm Brings In Israeli AI Financial Watchdog
November 27, 2023
Facebook comments